Affymetrix

The release has been accompanied by acute interest from the genomics community, which views the resource as a "game changer" for anyone working in human genetics.

Cytox Raises £2.6M

The British genetics company will use the proceeds to support the roll out of its Alzheimer's disease testing service.

The British molecular diagnostics company plans to make its array-based test for early-stage Alzheimer's disease available in the US by year end.

The company plans to outlicense the assay, developed using a custom Affymetrix microarray, to an interested partner.

The new algorithm, called TOPSPIN, complements the company's MMprofiler test. It is considering making TOPSPIN-generated data available to its MMprofiler patients.

Mergers and acquisitions in the omics space rose for the second year in a row, but the increase was significantly less than the 33 percent uptick in 2015 deals.

The company plans to use Thermo Fisher Scientific's newly launched PharmacoScan array-based platform for its testing.

The consortium aims to profile up to 800 multiple myeloma patient samples using the Affymetrix platform with a goal of developing a list of predictive biomarkers.

The first six months of the year have already seen some major deals announced, including big acquisitions by Abbott and Thermo Fisher Scientific.

Pages

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.